Curis
Curis
CRIS
NASDAQ
5.53
USD
80.13%
About
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS).
Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 124.2K |
| Three Month Average Volume | 999.3K |
| High Low | |
| Fifty-Two Week High | 17.49 USD |
| Fifty-Two Week Low | 3.8 USD |
| Fifty-Two Week High Date | 08 Apr 2024 |
| Fifty-Two Week Low Date | 25 Oct 2023 |
| Price and Volume | |
| Current Price | 5.525 USD |
| Beta | 3 |
| Relative Price Change | |
| Four Week Relative Price Change | 4.60% |
| Thirteen Week Relative Price Change | -50.17% |
| Twenty-Six Week Relative Price Change | -50.10% |
| Fifty-Two Week Relative Price Change | -60.58% |
| Year-to-Date Relative Price Change | -63.41% |
| Price Change | |
| One Day Price Change | 0.27% |
| Thirteen Week Price Change | -46.67% |
| Twenty-Six Week Price Change | -45.13% |
| Five Day Price Change | -11.60% |
| Fifty-Two Week Price Change | -50.60% |
| Year-to-Date Price Change | -56.67% |
| Month-to-Date Price Change | 0.82% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.33724 USD |
| Book Value Per Share (Most Recent Quarter) | -0.11754 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.81334 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.63881 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -8.53583 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.89353 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.75946 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -8.95718 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -8.2384 USD |
| Normalized (Last Fiscal Year) | -8.95718 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -8.95718 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -8.2384 USD |
| Including Extraordinary Items (Last Fiscal Year) | -8.95718 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -8.2384 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 9.55771 USD |
| Cash Per Share (Most Recent Quarter) | 4.8033 USD |
| Cash Flow Per Share (Last Fiscal Year) | -8.90901 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -8.19367 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -7.39974 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -355 |
| Cash Flow Revenue (Trailing Twelve Months) | -421 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -468.18% |
| Pretax Margin (Last Fiscal Year) | -473.04% |
| Pretax Margin (5 Year) | -409.44% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 97.88% |
| Gross Margin (Trailing Twelve Months) | 98.30% |
| Gross Margin (5 Year) | 96.05% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -482.21% |
| Operating Margin (Trailing Twelve Months) | -487.63% |
| Operating Margin (5 Year) | -377.89% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -473.04% |
| Net Profit Margin (Trailing Twelve Months) | -468.18% |
| Net Profit Margin (5 Year) | -409.44% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 15.89% |
| Revenue Growth (3 Year) | -0.79% |
| Revenue Change (Trailing Twelve Months) | -0.44% |
| Revenue Per Share Growth | -21.36% |
| Revenue Growth (5 Year) | -2.56% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 18.01% |
| EPS Change (Trailing Twelve Months) | 18.03% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -28,360,000 |
| Net Debt (Last Fiscal Year) | -56,334,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -38,434,000 |
| Free Cash Flow (Trailing Twelve Months) | -42,734,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -50.95% |
| Return on Assets (Trailing Twelve Months) | -70.62% |
| Return on Assets (5 Year) | -37.25% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -143.19% |
| Return on Equity (Trailing Twelve Months) | -372.68% |
| Return on Equity (5 Year) | -87.57% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -58.32% |
| Return on Investment (Trailing Twelve Months) | -90.04% |
| Return on Investment (5 Year) | -41.12% |